Live Stock Vaccine Market

Live Stock Vaccine Market Outlook for 2024 to 2034

The livestock vaccine market is predicted to be valued at USD 6.1 billion in 2024 and rise to USD 11.2 billion by 2034. The market is expected to grow at a CAGR of 6.2% during the forecast period.

Key Market Drivers

With the objective of giving the animal a vaccine to stimulate the immune system to form antibodies for the upliftment of their well-being, there is a huge rise in the livestock vaccine market. Some factors are mentioned below-

• The increasing demand for protein-rich diets, especially meat and dairy products, is leading to the need for healthy livestock populations and a surge in the demand for vaccines to prevent diseases.
• Rise in the prevalence of diseases among livestock causes significant economic loss. Thus, vaccination is becoming a crucial preventive measure for controlling and managing diseases effectively.
• With increasing government initiatives to eradicate livestock diseases, aiming to enhance food security and public health, demand for vaccination increasing.
• Ongoing innovations in biotechnology and genetic engineering enhance the efficacy and convenience of vaccination, encouraging their adoption among livestock producers.
• Livestock vaccines play a crucial role in preventing zoonotic diseases at their source, as there is an emphasis on the prevention of zoonotic diseases that can be transmitted between animals and humans.
• Rapid expansion in the livestock industry in emerging markets is driven by urbanization, rising disposable incomes, and changing dietary preferences. This serves as an opportunity for vaccine manufacturers to meet the increasing demand for livestock vaccines.
• With the globalization of trade in livestock and livestock products, vaccination plays a crucial role in mitigating this risk by ensuring the health and biosecurity of livestock populations.

Attributes	Key Statistics
Live Stock Vaccine Market Value (2024)	USD 6.1 billion
Anticipated Market Value (2034)	USD 11.2 billion
Estimated Growth (2024 to 2034)	6.2 % CAGR

Diverse Applications of Live Stock Vaccine

Despite the healthy growth of the livestock vaccine market in healthcare sectors, several factors are slowing down the market.

• Livestock producers are increasingly seeking to ensure consistent livestock health to ensure a reliable supply of high-quality products for consumers.
• In the livestock industry, there is a shift towards proactive and preventive healthcare practices, resulting in a preference for vaccination over curative treatments.
• Vaccines are viewed as cost-effective, reliable, and environment-friendly means of disease prevention, which urges widespread adoption.
• The surge in the sales of livestock vaccines to prevent outbreaks affecting livestock, producers prioritize disease control measures to protect their herds and mitigate losses.
• During trade restrictions or disease-related trade bans, there is a heightened demand for livestock vaccines to ensure compliance with biosecurity regulations and maintain access to export markets. This results in increased sales and adoption of vaccines.
• Continued investments in research and development drive innovation in the livestock vaccine market. New and improved vaccines enhance their popularity among livestock producers, compelling market growth and sales.

Challenges Impeding Growth in the Live Stock Vaccine Market

• Strict regulatory requirements for vaccine approval and registration can delay market entry and increase development costs.
• Limited awareness among livestock producers about the importance and benefits of vaccination can inhibit market growth.
• Inadequate infrastructure and limited access to cold chain facilities in remote or rural areas can affect vaccine distribution and efficacy.
• High upfront costs associated with implementing vaccination programs, including vaccine procurement, storage, and administration, can dissuade adoption, especially among small-scale farmers.
• Perceived or actual issues related to vaccine efficacy, such as low effectiveness against certain strains of pathogens, can undermine confidence in vaccination programs.
• Inadequate biosecurity measures on farms, such as poor sanitation practices and lack of quarantine protocols increases the risk of disease transmission and reduce the effectiveness of vaccination efforts.
• Insufficient funding for research and development in veterinary vaccines may limit innovation and the development of new and improved vaccine formulations.

Category-wise Insights

Broader Spectrum Coverage of Inactivated Vaccine Aids in Market Development

Inactivate vaccines ensure quality assurance and validation, upsurging the global livestock vaccine market with a 6.0% CAGR through 2034.

Attributes	Details
Top Type	Inactivated
CAGR (2024 to 2034)	6.0%

• Efficacy, safety, and regulatory compliance make inactivated vaccines top choice in the livestock vaccine market. These vaccines contain killed pathogens or antigens, making them suitable for a wide range of livestock species without the risk of causing disease.
• Manufacturers prefer inactivated vaccines as they have a longer shelf life and do not require strict cold chain storage, facilitating distribution and administration in diverse geographical regions.
• Inactivated vaccines possess established safety profiles and compatibility with breeding animals and young livestock, further contributing to their popularity among producers and veterinarians.

Large Market Size and Global Importance of Bovine Vaccine

Bovine vaccines are crucial in economic and productivity concerns, heightening the global livestock vaccine market by 5.8% CAGR from 2024 to 2034.

Attributes	Details
Top Animal Type	Bovine
CAGR (2024 to 2034)	5.8%

• Enormous economic importance of cattle farming worldwide makes bovine vaccines a highly favorable choice in the livestock vaccine market.
• Cattle contribute to a significant portion of the global livestock population and are essential for meat, dairy, and leather production. Farmers and producers maintain the health and productivity of their cattle herds for better outcomes.
• Bovine vaccines are specifically designed to combat prevalent diseases such as bovine viral diarrhea (BVD), bovine respiratory syncytial virus (BRSV), and infectious bovine rhinotracheitis (IBR). These diseases significantly affect productivity and cause economic downtrend in industry.

Country-wise Insights

The section analyzes the global livestock vaccine market by country, including the United Kingdom, the United States, China, South Korea, and Japan.

The table presents the CAGR for each country, indicating the expected market growth through 2034.

Countries	CAGR (2024 to 2034)
South Korea	8.0%
Japan	7.9%
United Kingdom	7.4%
China	6.8%
United States	6.4%

Expansion of the South Korea's Livestock Vaccine Market Due to Increased Disease Prevention Awareness

With growing demand for personalized medicine and advancements in precision healthcare, South Korea is well-positioned to capitalize on the opportunities presented by the expanding global livestock vaccine market with a CAGR of 8.0% from 2024 to 2034.

South Korea is investing in research and development to create innovative vaccine solutions to cater to the needs of the livestock sector. The market presents opportunities for collaborations with global vaccine manufacturers to introduce advanced technologies, expansion of vaccine production capabilities to meet both domestic and international demand, and the adoption of digital solutions for efficient vaccine distribution and administration.

South Korea's innovation in the field includes the development of novel vaccine delivery systems such as edible vaccines that offer convenience and improved efficacy. Future plans involve partnerships between public and private sectors to establish advance vaccine manufacturing facilities and enhance biosecurity measures to prevent disease outbreaks.

Market Expansion in Japan Driven by Increased Livestock Production

Japan is flourishing in the livestock vaccine market due to the country's growing emphasis on food safety, animal health, and sustainable agriculture. The market has a CAGR of 7.9%, which is expected to continue through 2034.

Japan is investing heavily in research and development, with a particular focus on improving the efficacy and safety of livestock vaccines. Collaboration between government agencies, academic institutions, and pharmaceutical companies is also on the rise, as they work together to create innovative vaccine solutions customized to meet the unique needs of the local livestock industry.

Notable organizations driving this growth include the National Institute of Animal Health and the Japan Livestock Technology Association, both actively engaged in vaccine research and development.

Emphasis on Technological Advancements Propelling Market Growth in the United Kingdom

The livestock vaccine market in the United Kingdom is projected to expand at a CAGR of 7.4% through 2034.

The United Kingdom is expanding with increased awareness of animal health and welfare. Growing Concerns about zoonotic diseases and government initiatives to support sustainable agriculture are uplifting the market growth. The United Kingdom is approaching this expansion by investing in research and development, fostering collaborations between academia and industry, and implementing regulatory measures to ensure the safety and efficacy of veterinary vaccines.

Famous centers such as the Pirbright Institute and the Roslin Institute play a crucial role in vaccine research and development, contributing to the expansion of the market. Upcoming projects like the United Kingdom Vaccine Manufacturing and Innovation Centre (VMIC) aim to strengthen the country's vaccine manufacturing capabilities and support the production of vaccines for livestock diseases.

Rising Demand and Modernization Soar the Livestock Vaccine Market in China

China is emerging as a key player in the livestock vaccine market. The market is projected to rise at a CAGR of 6.8% from 2024 to 2034. China is in a steady race to improve its veterinary healthcare sector.

Chinese government has made considerable efforts and investments in veterinary vaccines, prioritizing the health of livestock and food safety. These initiatives include research and development aimed at innovating vaccine formulations to tackle local disease challenges and production systems.

China has been actively promoting the use of vaccination programs among livestock producers through subsidies and educational campaigns, resulting in increased adoption rates. The demand for animal protein is also on the rise, along with the growth of the livestock industry leading to an escalating need for effective disease prevention measures in China.

Increasing Demand for Protein-Rich Diets and Government Support Drives the United States Market

Ongoing advancement and research in the United States soar market growth, with an expected CAGR of 6.4% until 2034.

The livestock vaccine market in the United States is expanding due to several factors. Innovative developments in veterinary vaccines, such as the introduction of novel formulations and delivery methods, have spurred growth by enhancing vaccine efficacy and safety. Research projects focused on improving disease prevention and management have contributed to market expansion, with initiatives aimed at addressing emerging livestock diseases and increasing vaccine accessibility.

Notable companies driving this growth include Zoetis, Merck Animal Health, and Elanco, which have a strong presence in the United States to develop cutting-edge vaccine solutions tailored to the needs of American livestock producers.

Competitive Landscape

Manufacturers and major companies are taking proactive measures to expand their market presence, as they are witnessing high demand in the livestock vaccine market. Companies such as Zoetis, Merck Animal Health, and Elanco are investing in research and development to create innovative vaccine formulations and delivery methods, which enhance the efficacy and safety of the vaccines.

With the growing global demand for protein-rich diets and increased awareness of animal health and welfare, there are significant opportunities for manufacturers to capitalize on the expanding livestock vaccine market. Some of the emerging trends in this market, such as personalized vaccination programs and the development of vaccines for emerging diseases, present promising avenues for growth and differentiation.

Recent Developments

• On December 28, 2023, Indian Immunologicals (IIL), a biotechnology firm under the National Dairy Development Board (NDDB), initiated construction of its new vaccine manufacturing plant in Genome Valley, Hyderabad. The company had invested approximately Rs 700 crore in the facility.
• On February 23, 2024, Bangladeshi Fisheries and Livestock Minister Abdur Rahman announced the government's intention to produce foot and mouth disease (FMD) vaccine locally in response to the rapid growth of the domestic FMD vaccine market.
• On January 9, 2024, Zhengye Biotechnology (ZYBT), a livestock vaccine manufacturer that sells vaccines in China and other countries, filed for a $20M US IPO.
• On July 28, 2023, the Yobe State Government procured 1.5 million doses of anthrax vaccine for livestock. The move aimed to mitigate the spread of anthrax disease among animals.

Key Companies in the Market

• Boehringer Ingelheim International GmbH
• Virbac
• Merck Animal Health
• Ceva, Elanco

Key Coverage in the Live Stock Vaccine Market Report

• Detailed Study in Advances in Irradiated Livestock Vaccine Research
• Analysis of the Animal Vaccine Industry
• Vaccinations for the Beef Cattle Herd Demand Analysis
• Market Analysis on Veterinary Immunization Products
• Insights into the Types of Vaccines for Animals
• Difference Between 7 in 1 Vaccine For Cattle and 3 in 1 Vaccine For Cattle

Table of Content

• 1. Executive Summary
• 2. Market Overview
• 3. Market Background
• 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
  • 4.1. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Type
    • 4.1.1. Inactivated
    • 4.1.2. Live Attenuated
    • 4.1.3. Recombinant
    • 4.1.4. Others
  • 4.2. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Animal Type
    • 4.2.1. Bovine
    • 4.2.2. Swine/Porcine
    • 4.2.3. Poultry
    • 4.2.4. Others
  • 4.3. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration
    • 4.3.1. Oral
    • 4.3.2. Parenteral
    • 4.3.3. Others
  • 4.4. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
    • 4.4.1. Veterinary Hospitals
    • 4.4.2. Veterinary Clinics
    • 4.4.3. Others
  • 4.5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
    • 4.5.1. North America
    • 4.5.2. Latin America
    • 4.5.3. Western Europe
    • 4.5.4. Eastern Europe
    • 4.5.5. South Asia and Pacific
    • 4.5.6. East Asia
    • 4.5.7. Middle East and Africa
  • 5. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
  • 6. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
  • 7. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
  • 8. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
  • 9. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
  • 10. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
  • 11. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
  • 12. Key Countries Market Analysis
  • 13. Market Structure Analysis
  • 14. Competition Analysis
    • 14.1. Boehringer Ingelheim International GmbH
    • 14.2. Virbac
    • 14.3. Merck Animal Health (Merck & Co., Inc.)
    • 14.4. Zoetis Services LLC
    • 14.5. Ceva
    • 14.6. Elanco
    • 14.7. HIPRA
    • 14.8. Neogen Corporation
    • 14.9. Dechra Pharmaceuticals PLC
    • 14.10. Biogénesis Bagó
  • 15. Assumptions & Acronyms Used
  • 16. Research Methodology